Benzinga · Aug 28, 2026
Citigroup Maintains Neutral on Veeva Systems, Raises Price Target to $273
Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:VEEV) with a Neutral and raises the price target from $190 to $273.

NYSE · VEEV
Healthcare · Medical - Healthcare Information Services
$276.69
Down-$5.44 (-1.93%)
Updated Aug 31, 2026, 9:51 AM
SID Score
6.7/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VEEV closed at $276.69 after 20 trading sessions, up 34.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $280.00 | $284.68 | $276.45 | $276.69 | 3.64M |
| Aug 27, 2026 | $275.355 | $296.24 | $274.81 | $282.13 | 6.41M |
| Aug 26, 2026 | $239.87 | $247.70 | $238.93 | $244.91 | 1.46M |
| Aug 25, 2026 | $244.27 | $247.85 | $242.53 | $246.78 | 1.62M |
| Aug 24, 2026 | $247.06 | $249.24 | $242.03 | $248.46 | 1.57M |
| Aug 21, 2026 | $250.74 | $250.81 | $246.80 | $247.90 | 1.09M |
| Aug 20, 2026 | $250.00 | $253.4899 | $246.00 | $250.53 | 1.31M |
| Aug 19, 2026 | $243.30 | $252.97 | $242.755 | $251.00 | 1.8M |
| Aug 18, 2026 | $243.17 | $247.025 | $241.72 | $242.75 | 1.52M |
| Aug 17, 2026 | $241.00 | $244.205 | $238.32 | $238.34 | 1.01M |
| Aug 14, 2026 | $251.80 | $253.48 | $243.49 | $243.75 | 1.43M |
| Aug 13, 2026 | $241.91 | $253.35 | $239.50 | $252.64 | 2.59M |
| Aug 12, 2026 | $232.53 | $241.74 | $230.17 | $241.51 | 1.78M |
| Aug 11, 2026 | $233.46 | $238.97 | $231.78 | $236.58 | 1.65M |
| Aug 10, 2026 | $228.86 | $236.00 | $228.37 | $234.69 | 1.79M |
| Aug 7, 2026 | $224.35 | $231.66 | $223.31 | $230.47 | 2.57M |
| Aug 6, 2026 | $209.00 | $217.95 | $208.07 | $217.80 | 2.2M |
| Aug 5, 2026 | $212.85 | $214.245 | $210.4401 | $213.51 | 1.55M |
| Aug 4, 2026 | $205.00 | $212.34 | $204.68 | $211.86 | 1.48M |
| Aug 3, 2026 | $209.99 | $211.56 | $205.635 | $206.25 | 2.61M |
The latest Smart Investors Daily articles mentioning VEEV.
VEEV research
Company profile and research snapshot.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Citigroup | Neutral | — |
| Aug 27, 2026 | UBS | Neutral | — |
| Aug 27, 2026 | Barclays | Overweight | — |
| Aug 27, 2026 | TD Cowen | Buy | — |
| Aug 27, 2026 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:VEEV) with a Neutral and raises the price target from $190 to $273.
SeekingAlpha · Aug 28, 2026
Veeva Systems Inc. Q2 revenue growth hit 18%, beating guidance. $2B buyback boosts EPS and strong balance sheet adds safety. Click for this VEEV stock update.
Fintel · Aug 28, 2026
Benzinga · Aug 27, 2026
Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:VEEV) with a Outperform and raises the price target from $270 to $280.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning VEEV.